EHA 2018 | MRD is the best predictor for treatment success in AML
Measurable residual disease (MRD) is gaining traction not only as a prognostic indicator, but also as a tool for informing treatment plans. In this video, recorded at the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Fabio Guolo, MD, of the University of Genoa, Genoa, Italy, speaks about his recent project that attempted to link MRD status prior to allogenic stem cell transplant with patient outcome in acute myeloid leukemia (AML). The results of this study indicated that MRD status is a better predictor for treatment success than any other risk factor, such as age and patient condition. Dr Guolo emphasises the potential for incorporating MRD into risk assessments for treatments like stem cell transplant, in order to tailor treatment plans more effectively.
